Vol 5, No 1 (February 29, 2016): Chinese Clinical Oncology

Editorial

Sonic hedgehog signaling pathway and gallbladder cancer: targeting with precision medicine approach
Naoko Takebe, Sherry X. Yang
Chinese Clinical Oncology  
2016;
5
(1)
:1
.
Targeting the hedgehog pathway for gallbladder cancer therapy?
Balraj Mittal, Saurabh Yadav
Chinese Clinical Oncology  
2016;
5
(1)
:2
.

Original Article

The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer
Willem A. van der Kloot, Yuka Uchida, Kenichi Inoue, Kunihiko Kobayashi, Kazue Yamaoka, Hans W. R. Nortier, Ad A. Kaptein
Chinese Clinical Oncology  
2016;
5
(1)
:3
.
Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?
Yi-Zarn Wang, Aman Chauhan, Jeffrey Rau, Anne E. Diebold, Adwoa Opoku-Boateng, Thiagarajan Ramcharan, J. Philip Boudreaux, Eugene A. Woltering
Chinese Clinical Oncology  
2016;
5
(1)
:4
.
Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab
Atsushi Yonezawa, Cariad Chester, Narendiran Rajasekaran, Holbrook E. Kohrt
Chinese Clinical Oncology  
2016;
5
(1)
:5
.
β-catenin and SKP2 proteins as predictors of grade and stage of non-muscle invasive urothelial bladder carcinoma
Eid Elsherif, Tarek Abdel Elbaky, Fatma Elserafy, Noha Elkady, Marwa Dawood, Mohamed Abdel Gaber, Atef Badawy, Mohamed El Gharabawy
Chinese Clinical Oncology  
2016;
5
(1)
:6
.
The supportive care needs for prostate cancer patients in Sarawak
Whye Lian Cheah, Ngok Chuo Ling, Kam Hock Chang
Chinese Clinical Oncology  
2016;
5
(1)
:7
.
Anticipatory extended cholecystectomy: the ‘Lucknow’ approach for thick walled gall bladder with low suspicion of cancer
Vinay K. Kapoor, Rakesh Singh, Anu Behari, Supriya Sharma, Ashok Kumar, Anand Prakash, Rajneesh Kumar Singh, Ashok Kumar, Rajan Saxena
Chinese Clinical Oncology  
2016;
5
(1)
:8
.

Review Article

Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges
Ioannis T. Konstantinidis, Nikolaos Arkadopoulos, Cristina R. Ferrone
Chinese Clinical Oncology  
2016;
5
(1)
:9
.

Statistics in Oncology Clinical Trials1

Phase III design: principles
Marc Buyse
Chinese Clinical Oncology  
2016;
5
(1)
:10
.
Statistical aspect of translational and correlative studies in clinical trials
Herbert Pang, Xiaofei Wang
Chinese Clinical Oncology  
2016;
5
(1)
:11
.

Guideline

Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo, Jianhui Ma, Yan Sun, Shukui Qin, Dingwei Ye, Fangjian Zhou, Zhisong He, Xinan Sheng, Feng Bi, Dengfeng Cao, Yingxia Chen, Yiran Huang, Houjie Liang, Jiwei Liu, Wenchao Liu, Yueyin Pan, Yongqian Shu, Xin Song, Weibo Wang, Xiuwen Wang, Xiaoan Wu, Xiaodong Xie, Xin Yao, Shiying Yu, Yanqiao Zhang, Aiping Zhou, written on behalf of CSCO Renal Cell Carcinoma Committee
Chinese Clinical Oncology  
2016;
5
(1)
:12
.

Perspective

CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study
Stephanie O. van der Woude, Maarten C.C.M. Hulshof, Hanneke W.M. van Laarhoven
Chinese Clinical Oncology  
2016;
5
(1)
:13
.

Disclosure:

1. The series “Statistics in Oncology Clinical Trials” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Daniel J. Sargent and Qian Shi served as the unpaid Guest Editors for the series.